The COVID-19 pandemic disproportionately disrupts the daily lives of marginalized populations. Persons with substance use disorders are a particularly vulnerable population because of their unique social and health care needs. They face significant harm from both the pandemic itself and its social and economic consequences, including marginalization in health care and social systems. Hence, we discuss: (1) why persons with substance use disorders are at increased risk for infection with COVID-19 and a severe illness course; (2) anticipated adverse consequences of COVID-19 in persons with substance use disorders; (3) challenges to health care delivery and substance use treatment programs during and after the COVID-19 pandemic; and (4) the potential impact on clinical research in substance use disorders. We offer recommendations for clinical, public health, and social policies to mitigate these challenges and to prevent negative outcomes.
TanneJH, HayasakiE, ZastrowM, PullaP, SmithP, RadaAG. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide. BMJ. 2020;368:m1090.
2.
VolkowND. Collision of the COVID-19 and addiction epidemics. Ann Intern Med. 2020. [epub ahead of print].
3.
BrownEE, KumarS, RajjiTK, PollockBG, MulsantBH. Anticipating and mitigating the impact of COVID-19 pandemic on Alzheimer's disease and related dementias. Am J Geriatr Psychiatry. 2020. [epub ahead of print].
4.
KozloffN, MulsantB, StergiopoulosV, VoineskosA. The COVID-19 global pandemic: implications for people with schizophrenia and related disorders. Schizophr Bull.2020. [epub ahead of print].
5.
YaoH, ChenJH, XuYF. Patients with mental health disorders in the COVID-19 epidemic. Lancet Psychiatry. 2020;7(4):e21.
GaleaS, VlahovD. Social determinants and the health of drug users: socioeconomic status, homelessness, and incarceration. Public Health Rep. 2002;117(1):S135–S145.
8.
GuydishJ, PassalacquaE, PaganoA, . An international systematic review of smoking prevalence in addiction treatment. Addiction. 2016;111(2):220–230.
9.
PalmerF, JaffrayM, MoffatMA, . Prevalence of common chronic respiratory diseases in drug misusers: a cohort study. Prim Care Respir J. 2012;21(4):377–383.
10.
ClementS, SchaumanO, GrahamT, . What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychol Med. 2015;45(1):11–27.
11.
van BoekelLC, BrouwersEP, van WeeghelJ, GarretsenHF. Comparing stigmatising attitudes towards people with substance use disorders between the general public, GPs, mental health and addiction specialists and clients. Int J Soc Psychiatry. 2015;61(6):539–549.
12.
TsaiJ, WilsonM. COVID-19: a potential public health problem for homeless populations. Lancet Public Health. 2020;5(4):e186–e187.
13.
BauerCMT, MorissetteMC, StampfliMR. The influence of cigarette smoking on viral infections: translating bench science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest. 2013;143(1):196–206.
14.
GatesP, JaffeA, CopelandJ. Cannabis smoking and respiratory health: consideration of the literature. Respirology. 2014;19(5):655–662.
15.
WalkerPP, ThwaiteE, AminS, CurtisJM, CalverleyP. The association between heroin inhalation and early onset emphysema. Chest. 2015;148(5):1156–1163.
16.
LoftisJM, HuckansM. Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy. Pharmacol Ther. 2013;139(2):289–300.
17.
KendlerKS, OhlssonH, SundquistK, SundquistJ. Drug abuse-associated mortality across the lifespan: a population-based longitudinal cohort and co-relative analysis. Soc Psychiatry Psychiatr Epidemiol. 2017;52(7):877–886.
18.
WuZ, McGooganJM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239.
19.
VardavasCI, NikitaraK. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20.
20.
LippiG, HenryBM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). Eur J Intern Med. 2020;75:107–108.
21.
DrussBG, von EsenweinSA. Improving general medical care for persons with mental and addictive disorders: systematic review. Gen Hosp Psychiatry. 2006;28(2):145–153.
22.
KimTW, SametJH, ChengDM, . The spectrum of unhealthy drug use and quality of care for hypertension and diabetes: a longitudinal cohort study. BMJ Open. 2015;5(12):e008508.
23.
EmanuelEJ, PersadG, UpshurR, . Fair allocation of scarce medical resources in the time of COVID-19. N Engl J Med. 2020;382(21):2049–2055.
24.
VolkowND, KoobGF, McLellanAT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363–371.
25.
al'AbsiM, CarrSB, BongardS. Anger and psychobiological changes during smoking abstinence and in response to acute stress: prediction of smoking relapse. Int J Psychophysiol. 2007;66(2):109–115.
26.
BlaineSK, SinhaR. Alcohol, stress, and glucocorticoids: from risk to dependence and relapse in alcohol use disorders. Neuropharmacology. 2017;122:136–147.
27.
ChaoT, RadoncicV, HienD, BediG, HaneyM. Stress responding in cannabis smokers as a function of trauma exposure, sex, and relapse in the human laboratory. Drug Alcohol Depend. 2018;185:23–32.
28.
PrestonKL, EpsteinDH. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology (Berl). 2011;218(1):29–37.
29.
BonnetU, PreussUW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9–37.
30.
GreenTC, BratbergJ, FinnellDS. Opioid use disorder and the COVID 19 pandemic: A call to sustain regulatory easements and further expand access to treatment. Subst Abus. 2020;41(2):147–149.
31.
BeckerWC, FiellinDA. When epidemics collide: Coronavirus Disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020. [epub ahead of print].
32.
AkiyamaMJ, SpauldingAC, RichJD. Flattening the curve for incarcerated populations - Covid-19 in jails and prisons. N Engl J Med. 2020;382(22):2075–2077.
33.
JoudreyPJ, KhanMR, WangEA, . A conceptual model for understanding post-release opioid-related overdose risk. Addict Sci Clin Pract. 2019;14(1):17.
34.
QiuJ, ShenB, ZhaoM, WangZ, XieB, XuY. A nationwide survey of psychological distress among Chinese people in the COVID-19 epidemic: implications and policy recommendations. Gen Psychiatr. 2020;33(2):e100213.
35.
CavaMA, FayKE, BeanlandsHJ, McCayEA, WignallR. The experience of quarantine for individuals affected by SARS in Toronto. Public Health Nurs. 2005;22(5):398–406.
36.
LeeAM, WongJG, McAlonanGM, . Stress and psychological distress among SARS survivors 1 year after the outbreak. Can J Psychiatry. 2007;52(4):233–240.
37.
ComptonWM, ThomasYF, StinsonFS, GrantBF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566–576.
38.
GoedersNE. Stress, motivation, and drug addiction. Curr Dir Psychol Sci. 2004;13(1):33–35.
DutraL, StathopoulouG, BasdenSL, LeyroTM, PowersMB, OttoMW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165(2):179–187.
ZaheerS, GarofaloV, RodieD, . Computer-aided telephone support for primary care patients with common mental health conditions: randomized controlled trial. JMIR Ment Health. 2018;5(4):e10224.
44.
QuanbeckA, ChihMY, IshamA, GustafsonD. Mobile delivery of treatment for alcohol use disorders: a review of the literature. Alcohol Res Curr Rev. 2014;36(1):111–122.
45.
LeghaRK, MooreL, LingR, NovinsD, ShoreJ. Telepsychiatry in an Alaska native residential substance abuse treatment program. Telemed J e-Health. 2019. [epub ahead of print].
46.
VarkerT, BrandRM, WardJ, TerhaagS, PhelpsA. Efficacy of synchronous telepsychology interventions for people with anxiety, depression, posttraumatic stress disorder, and adjustment disorder: a rapid evidence assessment. Psychol Serv. 2019;16(4):621–635.
47.
HollanderJE, CarrBG. Virtually perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679–1681.
48.
MarschLA, DalleryJ. Advances in the psychosocial treatment of addiction: the role of technology in the delivery of evidence-based psychosocial treatment. Psychiatr Clin North Am. 2012;35(2):481–493.
49.
Substance Abuse and Mental Health Services Administration.2014. Results from the 2013 National Survey on Drug Use and Health: summary of national findings. NSDUH Series H-48, HHS Publication No.(SMA) 14-4863,1–143.
McDermottMM, NewmanAB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA. 2020;323(21):2135.
53.
Food and Drug Administration.FDA guidance on conduct of clinical trials of medical products during COVID-19 pandemic: guidance for industry, investigators, and institutional review boards. 2020. [epub ahead of print].
54.
National Institutes of Health.Guidance for NIH-funded clinical trials and human subjects studies affected by COVID-19. 2020. [epub ahead of print].
